[{"id":"333f671c-7feb-492f-84ae-284d80aba06a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05876832","created_at":"2023-05-25T15:05:47.488Z","updated_at":"2024-07-02T16:35:47.080Z","phase":"Phase 3","brief_title":"A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)","source_id_and_acronym":"NCT05876832","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • XY0206"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 06/15/2023","start_date":" 06/15/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-05-26"},{"id":"265c0e3a-402e-40b9-8f6d-dbb577309908","acronym":"","url":"https://clinicaltrials.gov/study/NCT03658070","created_at":"2021-01-18T17:57:09.129Z","updated_at":"2024-07-02T16:36:41.784Z","phase":"Phase 1","brief_title":"A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT03658070","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XY0206"],"overall_status":"Unknown status","enrollment":" Enrollment 34","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-08-21"}]